|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Multi-institutional retrospective analysis of FOLFIRI in patients with advanced biliary tract cancers显示文摘BACKGROUND Gemcitabine plus platinum is the standard of care first-line treatment for advanced biliary tract cancers(BTC).There is no established second-line therapy,and retrospective reviews report median progression-free survival(PFS)less than 3 mo on second-line therapy.5-Fluorouracil plus irinotecan(FOLFIRI)is a commonly used regimen in patients with BTC who have progressed on gemcitabine plus platinum,though there is a paucity of data regarding its efficacy in this population.AIM To assess the efficacy of FOLFIRI in patients with biliary tract cancers.METHODS We retrospectively identified patients with advanced BTC who were treated with FOLFIRI at MD Anderson,University of Michigan and Mayo Clinic in Jacksonville.Data were collected on patient demographics,BTC subtype,response per RECIST v1.1,progression and survival.RESULTS Ninety-eight patients were included of which 74(75%)had metastatic and 24(25%)had locally advanced disease at the time of treatment with FOLFIRI.The median age was 60(range,22-86)years.The number of patients with extrahepatic cholangiocarcinoma,gall bladder cancer and intrahepatic cholangiocarcinoma were 10,17 and 71,respectively.FOLFIRI was used as 1st,2nd,3rd or 4th–Nth lines in 8,50,36 and 4 patients,respectively.Median duration on FOLFIRI in the entire cohort was 2.2(range,0.5-8.4)mo.The median PFS and overall survival were 2.4(95%confidence interval(CI):1.7-3.1)and 6.6(95%CI:4.7-8.4)mo,respectively.Median PFS for patients treated with FOLFIRI in 1st,2nd,3rd or 4th–Nth lines were 3.1,2.5,2.3 and 1.5 mo,respectively.Eighteen patients received concurrent bevacizumab(n=13)or EGFR-targeted therapy(n=5)with FOLFIRI,with a median PFS of 2.7 mo(95%CI:1.7-5.1).CONCLUSION In this largest multi-institution retrospective review of 98 patients with BTC treated with FOLFIRI,efficacy appears to be modest with outcomes similar to other cytotoxic chemotherapy regimens. | Jonathan D Mizrahi Valerie Gunchick Kabir Mody Lianchun Xiao Phanikeerthi Surapaneni Rachna T Shroff Vaibhav Sahai | 2020 | World Journal of Gastrointestinal Oncology2020，12，1： | 2 |
| 2 | Macrophage β2 integrin - mediated, HuR - dependent stabilization of angiogenic factor - encoding mRNAs in inflammatory angiogenesis 显示文摘 | Zhang J Modi Y Yarovinsky T | 2012 | Am J Pathol2012，180，4： | 1 |
| 3 | Parameterization and tes- ting of AquaCrop for a South African bambara groundnut landrace 显示文摘 | Mabhaudhi T Modi A T Beletse Y G | 2014 | Agronomy Journal2014，106，1： | 1 |
| 4 | Operative versus nonopemtive treatment of acute undisplaced and minimally displaced scaphoid waist fractures-a systematic review显示文摘 | Modi CS Nancoo T Powers D | 2009 | Injury2009，40，3： | 1 |
| 5 | Bridging the cleft at GABA synapses in the brain显示文摘 | MODY I DE KONINCK Y OTIS T S SOLTESZ I | 1994 | Trends in Neurosciences1994，17，： | 1 |
| 6 | High performance thin-layer chromatographic method for the determination of sparfloxacin in human plasma and its use in pharmacokinetic stusies显示文摘 | May D V Pandys K K Satia M C Modi I A Modi I R Gandhi T P | 1998 | J Pharm Biomed Anal1998，16，8： | 1 |
| 7 | Two-repeat Tetrahymena telomeric d(TGGGGTTGGGGT)sequence interconverts between asymmetric dimeric Gquadruplexes in solution显示文摘 | PHAN A T MODI Y S PATEL D J | 2004 | J Mol Biol2004，338，1： | 1 |
| 8 | Effect of testing conditions and microstructure on the sliding wear of graphite fibre/PEEK matrix composites显示文摘 | MODY P B CHOU T W FRIEDRICH K | 1998 | J Mater Sci1998，，23： | 1 |
| 9 | Serumretinol binding protein 4 contributes to insulin resist-ance in obesity and type 2 diabetes 显示文摘 | YANG Q GRAHAM T E MODY N | 2005 | Nafwre2005，436，7049： | 1 |
| 10 | Opera- tive versus nonoperative treatment of acute undisplaced and minimally displaced scaphoid waist fractures-a systematic review 显示文摘 | Modi CS Nancoo T Powers D | 2009 | Injury2009，40，3： | 1 |
| 11 | Serum retinol-bindingprotein 4contributes to insulin resistance in obesity and type 2diabetes显示文摘 | Yang Q Graham T E Mody N | 2005 | Nature2005，436，7049： | 1 |
| 12 | Technological forecasting at the stock market显示文摘 | Modis T | 1999 | Technological Forecasting and Social Change1999，，62： | 1 |
| 13 | Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase- 4 inhibitor in male type 2 diabetes patients显示文摘 | HEISE T GRAEFE- MODY EU HUTTNER S | 2009 | Diabetes Obes Metab2009，11，8： | 1 |
| 14 | Azacytidine(Vidaza) treatment response assessed using three alternative dosing schedules in patients with myelodysplastic syndromes显示文摘 | Lyons R Cosgriff T Modi S | 2005 | Blood2005，106，： | 1 |
| 15 | Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes显示文摘 | Yang Q Graham T E Mody N | 2005 | Nature2005，436，21： | 1 |
| 16 | CT depiction of pulmonary emboli:display window settings显示文摘 | Bae K T Mody G N Balfe D M | | 0，，2： | 1 |
| 17 | Technological forecasting at the stock markrts 显示文摘 | MODIS T | 1999 | Technological Forecasting and Social Change1999，62，： | 1 |
| 18 | Azacytidine(Vidaza) treatment response assessed using three alternative dosing schedules in patients with myelodysplastic syndromes 显示文摘 | Lyons R Cosgriff T Modi S | 2005 | Blood2005，106，： | 1 |
| 19 | Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes 显示文摘 | YANG Q GRAHAM T E MODY N | 2005 | Nature2005，436，： | 1 |
| 20 | estrogen and progesterone receptors in brongenic carcinoma 显示文摘 | Philip T Mody DR Schwartz MR | 1990 | Cancer Res1990，50，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员